{"id":"pn-400-vimovo","safety":{"commonSideEffects":[{"rate":"null","effect":"Gastrointestinal bleeding"},{"rate":"null","effect":"Abdominal pain"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3652526","moleculeType":"Small molecule","molecularWeight":"431.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By combining an NSAID with a proton pump inhibitor, VIMOVO aims to reduce the risk of gastrointestinal complications such as ulcers and bleeding, which are common side effects of NSAID therapy. This is particularly important for patients who require long-term NSAID treatment for conditions like osteoarthritis or rheumatoid arthritis.","oneSentence":"VIMOVO combines the NSAID ibuprofen with the proton pump inhibitor omeprazole to reduce gastrointestinal side effects associated with NSAID therapy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:14.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT00664560","phase":"PHASE3","title":"Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis","status":"COMPLETED","sponsor":"POZEN","startDate":"2008-04","conditions":"Osteoarthritis","enrollment":614},{"nctId":"NCT00665431","phase":"PHASE3","title":"Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis","status":"COMPLETED","sponsor":"POZEN","startDate":"2008-04","conditions":"Osteoarthritis","enrollment":610},{"nctId":"NCT01129011","phase":"PHASE3","title":"Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen","status":"COMPLETED","sponsor":"POZEN","startDate":"2007-09","conditions":"Gastric Ulcer","enrollment":420},{"nctId":"NCT00527787","phase":"PHASE3","title":"Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen","status":"COMPLETED","sponsor":"POZEN","startDate":"2007-09","conditions":"Gastric Ulcer","enrollment":434},{"nctId":"NCT00594854","phase":"PHASE3","title":"Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec","status":"TERMINATED","sponsor":"POZEN","startDate":"2007-09","conditions":"Gastric Ulcer","enrollment":20},{"nctId":"NCT00527904","phase":"PHASE3","title":"A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)","status":"COMPLETED","sponsor":"POZEN","startDate":"2007-03","conditions":"Gastric Ulcer","enrollment":239},{"nctId":"NCT00992381","phase":"PHASE1","title":"Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-09","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Naprosyn","Nexium","PN 400","PN400"],"phase":"phase_3","status":"active","brandName":"PN 400 (VIMOVO)","genericName":"PN 400 (VIMOVO)","companyName":"POZEN","companyId":"pozen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PN 400 (VIMOVO) is a small molecule used in the treatment of osteoarthritis. It has also been studied in relation to gastric ulcers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}